Metabolic control of tumour progression and antitumour immunity

Lei Huang, Andrew L. Mellor

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: Loss of cell growth control is not sufficient to explain why tumours form as the immune system recognizes many malignant cells and keeps them in check. The local inflammatory microenvironment is a pivotal factor in tumour formation, as tumour-associated inflammation actively suppresses antitumour immunity. The purpose of this review is to evaluate emerging evidence that amino acid catabolism is a key feature of tumour-associated inflammation that supports tumour progression and immune resistance to therapy. RECENT FINDINGS: Enhanced amino acid catabolism in inflammatory tumour microenvironments correlates with carcinogen resistance and immune regulation mediated by tumour-associated immune cells that protect tumours from natural and vaccine-induced immunity. Interfering with metabolic pathways exploited by tumours is a promising antitumour strategy, especially when combined with other therapies. Moreover, molecular sensors that evolved to detect pathogens may enhance evasion of immune surveillance to permit tumour progression. SUMMARY: Innate immune sensing that induces amino acid catabolism in tumour microenvironments may be pivotal in initiating and sustaining local inflammation that promotes immune resistance and attenuates antitumour immunity. Targeting molecular sensors that mediate these metabolic changes may be an effective strategy to enhance antitumour immunity that prevents tumour progression, as well as improving the efficacy of cancer therapy.

Original languageEnglish (US)
Pages (from-to)92-99
Number of pages8
JournalCurrent Opinion in Oncology
Volume26
Issue number1
DOIs
StatePublished - Jan 1 2014

Fingerprint

Immunity
Neoplasms
Tumor Microenvironment
Inflammation
Amino Acids
Immune Evasion
Cancer Vaccines
Metabolic Networks and Pathways
Carcinogens
Immune System
Therapeutics
Growth

Keywords

  • amino acid catabolism
  • antitumour immunity
  • innate immune sensors
  • interferons
  • tumour tolerance

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Metabolic control of tumour progression and antitumour immunity. / Huang, Lei; Mellor, Andrew L.

In: Current Opinion in Oncology, Vol. 26, No. 1, 01.01.2014, p. 92-99.

Research output: Contribution to journalReview article

Huang, Lei ; Mellor, Andrew L. / Metabolic control of tumour progression and antitumour immunity. In: Current Opinion in Oncology. 2014 ; Vol. 26, No. 1. pp. 92-99.
@article{1bdb5e4178d547888ebfd0d026b5088d,
title = "Metabolic control of tumour progression and antitumour immunity",
abstract = "PURPOSE OF REVIEW: Loss of cell growth control is not sufficient to explain why tumours form as the immune system recognizes many malignant cells and keeps them in check. The local inflammatory microenvironment is a pivotal factor in tumour formation, as tumour-associated inflammation actively suppresses antitumour immunity. The purpose of this review is to evaluate emerging evidence that amino acid catabolism is a key feature of tumour-associated inflammation that supports tumour progression and immune resistance to therapy. RECENT FINDINGS: Enhanced amino acid catabolism in inflammatory tumour microenvironments correlates with carcinogen resistance and immune regulation mediated by tumour-associated immune cells that protect tumours from natural and vaccine-induced immunity. Interfering with metabolic pathways exploited by tumours is a promising antitumour strategy, especially when combined with other therapies. Moreover, molecular sensors that evolved to detect pathogens may enhance evasion of immune surveillance to permit tumour progression. SUMMARY: Innate immune sensing that induces amino acid catabolism in tumour microenvironments may be pivotal in initiating and sustaining local inflammation that promotes immune resistance and attenuates antitumour immunity. Targeting molecular sensors that mediate these metabolic changes may be an effective strategy to enhance antitumour immunity that prevents tumour progression, as well as improving the efficacy of cancer therapy.",
keywords = "amino acid catabolism, antitumour immunity, innate immune sensors, interferons, tumour tolerance",
author = "Lei Huang and Mellor, {Andrew L.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1097/CCO.0000000000000035",
language = "English (US)",
volume = "26",
pages = "92--99",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Metabolic control of tumour progression and antitumour immunity

AU - Huang, Lei

AU - Mellor, Andrew L.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - PURPOSE OF REVIEW: Loss of cell growth control is not sufficient to explain why tumours form as the immune system recognizes many malignant cells and keeps them in check. The local inflammatory microenvironment is a pivotal factor in tumour formation, as tumour-associated inflammation actively suppresses antitumour immunity. The purpose of this review is to evaluate emerging evidence that amino acid catabolism is a key feature of tumour-associated inflammation that supports tumour progression and immune resistance to therapy. RECENT FINDINGS: Enhanced amino acid catabolism in inflammatory tumour microenvironments correlates with carcinogen resistance and immune regulation mediated by tumour-associated immune cells that protect tumours from natural and vaccine-induced immunity. Interfering with metabolic pathways exploited by tumours is a promising antitumour strategy, especially when combined with other therapies. Moreover, molecular sensors that evolved to detect pathogens may enhance evasion of immune surveillance to permit tumour progression. SUMMARY: Innate immune sensing that induces amino acid catabolism in tumour microenvironments may be pivotal in initiating and sustaining local inflammation that promotes immune resistance and attenuates antitumour immunity. Targeting molecular sensors that mediate these metabolic changes may be an effective strategy to enhance antitumour immunity that prevents tumour progression, as well as improving the efficacy of cancer therapy.

AB - PURPOSE OF REVIEW: Loss of cell growth control is not sufficient to explain why tumours form as the immune system recognizes many malignant cells and keeps them in check. The local inflammatory microenvironment is a pivotal factor in tumour formation, as tumour-associated inflammation actively suppresses antitumour immunity. The purpose of this review is to evaluate emerging evidence that amino acid catabolism is a key feature of tumour-associated inflammation that supports tumour progression and immune resistance to therapy. RECENT FINDINGS: Enhanced amino acid catabolism in inflammatory tumour microenvironments correlates with carcinogen resistance and immune regulation mediated by tumour-associated immune cells that protect tumours from natural and vaccine-induced immunity. Interfering with metabolic pathways exploited by tumours is a promising antitumour strategy, especially when combined with other therapies. Moreover, molecular sensors that evolved to detect pathogens may enhance evasion of immune surveillance to permit tumour progression. SUMMARY: Innate immune sensing that induces amino acid catabolism in tumour microenvironments may be pivotal in initiating and sustaining local inflammation that promotes immune resistance and attenuates antitumour immunity. Targeting molecular sensors that mediate these metabolic changes may be an effective strategy to enhance antitumour immunity that prevents tumour progression, as well as improving the efficacy of cancer therapy.

KW - amino acid catabolism

KW - antitumour immunity

KW - innate immune sensors

KW - interferons

KW - tumour tolerance

UR - http://www.scopus.com/inward/record.url?scp=84890458987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890458987&partnerID=8YFLogxK

U2 - 10.1097/CCO.0000000000000035

DO - 10.1097/CCO.0000000000000035

M3 - Review article

C2 - 24305570

AN - SCOPUS:84890458987

VL - 26

SP - 92

EP - 99

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 1

ER -